Serum Alpha-Fetoprotein Levels During and After Interferon Therapy and the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

  • Yasushi Tamura
  • Satoshi Yamagiwa
  • Yohei Aoki
  • So Kurita
  • Takeshi Suda
  • Shogo Ohkoshi
  • Minoru Nomoto
  • Yutaka Aoyagi
  • The Niigata Liver Disease Study Group
Original Article


The association between serum alpha-fetoprotein (AFP) levels during and after interferon (IFN) therapy and the development of hepatocellular carcinoma (HCC) was evaluated in patients with chronic hepatitis C (CHC). A total of 263 patients treated by IFN with or without ribavirin were enrolled in the study. Serum AFP levels during and after IFN therapy were investigated retrospectively, and statistical analysis was performed to identify the factors associated with HCC development. During IFN therapy, serum AFP levels significantly decreased, regardless of virologic response to treatment. Increased serum AFP levels (≥10 ng/ml) at the end of IFN therapy (EOT) was a close-to-significant variable affecting the development of HCC (P = 0.057), and a significantly higher cumulative incidence of HCC was seen in patients with increased serum AFP levels at EOT (P = 0.021). Serum AFP level at EOT is a possible predictor of HCC in CHC patients after IFN therapy.


Chronic hepatitis C Interferon Alpha-fetoprotein Hepatocellular carcinoma 



The following doctors at each of the institutions participating in the Niigata Liver Disease Study Group contributed equally to the study: Nobuo Waguri and Kentaro Igarashi (Niigata City General Hospital, Niigata), Toru Ishikawa and Tomoteru Kamimura (Saiseikai Niigata Second Hospital, Niigata), Motoya Sugiyama (Niigata Prefectural Shibata Hospital, Shibata), Soichi Sugitani (Tachikawa General Hospital, Nagaoka), Norio Ogata (Tsubame Rosai Hospital, Tsubame), Toru Hatano (Nagaoka Chuo General Hospital, Nagaoka), Toru Takahashi (Nagaoka Red Cross Hospital, Nagaoka), Hitoshi Bannai (Saiseikai Sanjo Hospital, Sanjo), Hiroto Wakabayashi (Takeda General Hospital, Aizuwakamatsu), Atsuo Sekine (Niigata Prefectural Yoshida Hospital, Tsubame), Toshiyuki Kato (Niigata Prefectural Cancer Center Hospital, Niigata), Masaaki Hirano (Niigata Prefectural Central Hospital, Joetsu), and Toru Miyajima (Toyosaka Hospital, Niigata).


  1. 1.
    Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989;334:1004–1046. doi: 10.1016/S0140-6736(89)91015-5.CrossRefGoogle Scholar
  2. 2.
    Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;334:1006–1008. doi: 10.1016/S0140-6736(89)91016-7.CrossRefGoogle Scholar
  3. 3.
    Hasan F, Jeffers LJ, De Medina M, et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology. 1990;12:589–591. doi: 10.1002/hep.1840120323.CrossRefPubMedGoogle Scholar
  4. 4.
    Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47–53.CrossRefPubMedGoogle Scholar
  5. 5.
    Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–1801. doi: 10.1056/NEJM199306243282501.CrossRefPubMedGoogle Scholar
  6. 6.
    Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501–1506.PubMedGoogle Scholar
  7. 7.
    Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–1510.PubMedGoogle Scholar
  8. 8.
    Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991;101:497–502.PubMedGoogle Scholar
  9. 9.
    Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology. 1991;13:1040–1043.CrossRefPubMedGoogle Scholar
  10. 10.
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–1055. doi: 10.1016/S0140-6736(95)91739-X.CrossRefPubMedGoogle Scholar
  11. 11.
    Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–1130. doi: 10.1002/hep.510290439.CrossRefPubMedGoogle Scholar
  12. 12.
    Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–1622. doi: 10.1002/cncr.20537.CrossRefPubMedGoogle Scholar
  13. 13.
    Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148–156. doi: 10.1007/s00535-004-1519-2.CrossRefPubMedGoogle Scholar
  14. 14.
    Abelev GI. Production of embryonal serum alpha-globulin by hepatoma: review of experimental and clinical data. Cancer Res. 1968;28:1344–1350.PubMedGoogle Scholar
  15. 15.
    Conor GI, Tatarinov YS, Abelev GI, Uriel J. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer. 1970;25:1091–1098. doi:10.1002/1097-0142(197005)25:5<1091::AID-CNCR2820250514>3.0.CO;2-P.CrossRefGoogle Scholar
  16. 16.
    Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol. 1998;93:2452–2456. doi: 10.1111/j.1572-0241.1998.00703.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Goldstein NS, Blue DE, Hankin R, et al. Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol. 1999;111:811–816.PubMedGoogle Scholar
  18. 18.
    Chu CW, Hwang SJ, Luo JC, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol. 2001;32:240–244. doi: 10.1097/00004836-200103000-00014.CrossRefPubMedGoogle Scholar
  19. 19.
    Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99:860–865. doi: 10.1111/j.1572-0241.2004.04152.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Di Bisceglie AM, Sterling RK, Chung RT, et al. HALT-C Trial group: serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434–441. doi: 10.1016/j.jhep.2005.03.019.CrossRefPubMedGoogle Scholar
  21. 21.
    Murashima S, Tanaka M, Haramaki M, et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci. 2006;51:808–812. doi: 10.1007/s10620-006-3211-2.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen TM, Huang PT, Tsai MH, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669–675.PubMedGoogle Scholar
  23. 23.
    Nomura H, Kashiwagi Y, Hirano R, et al. Efficacy of low-dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: a pilot study. Hepatol Res. 2007;37:490–497. doi: 10.1111/j.1872-034X.2007.00073.x.CrossRefPubMedGoogle Scholar
  24. 24.
    Arase Y, Suzuki F, Suzuki Y, et al. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol. 2008;80:1302–1307. doi: 10.1002/jmv.21195.CrossRefPubMedGoogle Scholar
  25. 25.
    Ichida F, Tsuji T, Omata M, et al. New Inuyama Classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996;6:112–119. doi: 10.1016/S0928-4346(96)00325-8.CrossRefGoogle Scholar
  26. 26.
    Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472. doi: 10.1053/gast.1997.v112.pm9024300.CrossRefPubMedGoogle Scholar
  27. 27.
    Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993;328:1802–1806. doi: 10.1056/NEJM199306243282502.CrossRefPubMedGoogle Scholar
  28. 28.
    Niwa Y, Matsumura M, Shiratori Y, et al. Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Hepatology. 1996;23:1384–1392.PubMedGoogle Scholar
  29. 29.
    Panduro A, Shalaby F, Weiner FR, Biempica L, Zern MA, Shafritz DA. Transcriptional switch from albumin to alpha-fetoprotein and changes in transcription of other genes during carbon tetrachloride induced liver regeneration. Biochemistry. 1986;25:1414–1420. doi: 10.1021/bi00354a034.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang XW, Xu B. Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer. 1998;75:596–599. doi:10.1002/(SICI)1097-0215(19980209)75:4<596::AID-IJC17>3.0.CO;2-7.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang XW, Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci. 1999;64:17–23. doi: 10.1016/S0024-3205(98)00529-3.CrossRefPubMedGoogle Scholar
  32. 32.
    Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol. 2004;10:819–824.PubMedGoogle Scholar
  33. 33.
    Li MS, Ma QL, Chen Q, et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol. 2005;11:2564–2569.PubMedGoogle Scholar
  34. 34.
    Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–121. doi: 10.1053/j.gastro.2008.03.073.CrossRefPubMedGoogle Scholar
  35. 35.
    Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–1213. doi: 10.1053/jhep.2002.36780.CrossRefPubMedGoogle Scholar
  36. 36.
    Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US. Cancer. 2004;101:1009–1017. doi: 10.1002/cncr.20427.CrossRefPubMedGoogle Scholar
  37. 37.
    Chiba T, Matsuzaki Y, Abei M, et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol. 1996;91:1195–1203.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Yasushi Tamura
    • 1
  • Satoshi Yamagiwa
    • 1
  • Yohei Aoki
    • 1
  • So Kurita
    • 1
  • Takeshi Suda
    • 1
  • Shogo Ohkoshi
    • 1
  • Minoru Nomoto
    • 1
  • Yutaka Aoyagi
    • 1
  • The Niigata Liver Disease Study Group
    • 2
  1. 1.Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental SciencesNiigata UniversityNiigataJapan
  2. 2.The Niigata Liver Disease Study GroupNiigataJapan

Personalised recommendations